keyword
MENU ▼
Read by QxMD icon Read
search

Haploidentical transplant

keyword
https://www.readbyqxmd.com/read/27909435/immune-reconstitution-after-allogeneic-hematopoietic-stem-cell-transplantation
#1
REVIEW
Justyna Ogonek, Mateja Kralj Juric, Sakhila Ghimire, Pavankumar Reddy Varanasi, Ernst Holler, Hildegard Greinix, Eva Weissinger
The timely reconstitution and regain of function of a donor-derived immune system is of utmost importance for the recovery and long-term survival of patients after allogeneic hematopoietic stem cell transplantation (HSCT). Of note, new developments such as umbilical cord blood or haploidentical grafts were associated with prolonged immunodeficiency due to delayed immune reconstitution, raising the need for better understanding and enhancing the process of immune reconstitution and finding strategies to further optimize these transplant procedures...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27905258/hla-mismatched-haploidentical-transplantation-using-low-dose-anti-thymocyte-globulin-atg-thymoglobulin
#2
Shinichi Kako, Yu Akahoshi, Naonori Harada, Hirofumi Nakano, Kazuaki Kameda, Tomotaka Ugai, Ryoko Yamasaki, Hidenori Wada, Yuko Ishihara, Koji Kawamura, Kana Sakamoto, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun-Ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Junya Kanda, Yoshinobu Kanda
Objectives To clarify optimal strategies for human leukocyte antigen (HLA)-mismatched haploidentical hematopoietic stem cell transplantation (HSCT). Methods Twelve patients who underwent HSCT from a haploidentical related donor using low-dose thymoglobulin were analyzed retrospectively. Thymoglobulin was added to conditioning regimens at 2.5 mg/kg/day for 2 days (days -4 and -3). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine and methotrexate. Results The median age of the patients was 33 years...
December 1, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27888540/higher-dose-of-cd34-peripheral-blood-stem-cells-is-associated-with-better-survival-after-haploidentical-stem-cell-transplantation-in-pediatric-patients
#3
Yao Chen, Lan-Ping Xu, Kai-Yan Liu, Huan Chen, Yu-Hong Chen, Xiao-Hui Zhang, Yu Wang, Feng-Rong Wang, Wei Han, Jing-Zhi Wang, Chen-Hua Yan, Xiao-Jun Huang
Haploidentical stem cell transplantation (SCT) is increasingly used to treat pediatric patients with malignant or non-malignant hematological disorders. The CD34+ dose of bone marrow or peripheral blood stem cells (PBSCs) has been shown to be an important determinant of the transplant outcome in adults under various preparative regimens. However, knowledge of the effect of the CD34+ dose in pediatric haploidentical SCT is limited. We analyzed the data of 348 pediatric patients (aged 2-18 years) with acute or chronic leukemia, myelodysplastic syndrome (MDS), and other hematological disorders that received a transplant between 2002 and 2012...
November 26, 2016: Clinical Transplantation
https://www.readbyqxmd.com/read/27888014/nonmyeloablative-haploidentical-bone-marrow-transplantation-with-post-transplant-cyclophosphamide-for-pediatric-and-young-adult-patients-with-high-risk-hematologic-malignancies
#4
Orly R Klein, Jessica Buddenbaum, Noah Tucker, Allen R Chen, Christopher J Gamper, David Loeb, Elias Zambidis, Nicolas J Llosa, Jeffrey S Huo, Nancy Robey, Mary Jo Holuba, Yvette L Kasamon, Shannon R McCurdy, Richard Ambinder, Javier Bolaños-Meade, Leo Luznik, Ephraim J Fuchs, Richard J Jones, Kenneth R Cooke, Heather J Symons
Lower intensity conditioning regimens for haploidentical blood or marrow transplantation (BMT) are safe and efficacious for adult patients with hematologic malignancies. We report data for pediatric/young adult patients with high-risk hematologic malignancies (n=40) treated with nonmyeloablative haploidentical BMT with post-transplantation cyclophosphamide (PT/Cy) from 2003-2015. Patients received a preparative regimen of fludarabine, cyclophosphamide, and total body irradiation. Post-transplant immunosuppression consisted of cyclophosphamide, mycophenolate mofetil, and tacrolimus...
November 22, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27885760/haploidentical-hematopoietic-stem-cell-transplantation-for-a-case-with-x-linked-chronic-granulomatous-disease
#5
Ling Zhou, Lu-Jia Dong, Zhi-Yong Gao, Xin-Jian Yu, Dao-Pei Lu
CGD is a rare primary immunodeficiency with high mortality rates when treated conventionally, especially for the X-chromosome-linked form. HSCT is the only curative therapy for CGD; however, haploidentical transplantation in CGD is rare. Here, we report a case of X-linked CGD treated successfully by haploidentical HSCT. The patient showed a positive result with full donor chimerism, good quality of life, and the absence of recurrent infectious diseases at follow-up (68 months). Thus, haploidentical HSCT may serve as an acceptable treatment approach for patients who have CGD, but no HLA-matched related or unrelated donor...
November 25, 2016: Pediatric Transplantation
https://www.readbyqxmd.com/read/27872737/immunity-to-infections-after-haploidentical-hematopoietic-stem-cell-transplantation
#6
REVIEW
Franco Aversa, Lucia Prezioso, Ilenia Manfra, Federica Galaverna, Angelica Spolzino, Alessandro Monti
The advantage of using a Human Leukocyte Antigen (HLA)-mismatched related donor is that almost every patient who does not have an HLA-identical donor or who urgently needs hematopoietic stem cell transplantation (HSCT) has at least one family member with whom shares one haplotype (haploidentical) and who is promptly available as a donor. The major challenge of haplo-HSCT is intense bi-directional alloreactivity leading to high incidences of graft rejection and graft-versus-host disease (GVHD). Advances in graft processing and pharmacologic prophylaxis of GVHD have reduced these risks and have made haplo-HSCT a viable alternative for patients lacking a matched donor...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27864604/the-long-term-outcome-of-reduced-intensity-allogeneic-stem-cell-transplantation-from-a-matched-related-or-unrelated-donor-or-haploidentical-family-donor-in-patients-with-leukemia-a-retrospective-analysis-of-data-from-the-china-ric-cooperative-group
#7
Chang-Lin Yu, Zheng-Dong, Zhen-Hua Qiao, Jian-Min Wang, Huang-He, Ying-Min Liang, De-Pei Wu, Bao-An Chen, Bai-Hai, Bao-Fu Shi, Wan-Jun Sun, Jun-Xiao Qiao, Mei Guo, Jian-Hui Qiao, Qi-Yun Sun, Kai-Xun Hu, Ya-Jing Huang, Hong-Li Zuo, Xiao-Jun Huang, Hui-Sheng Ai
This study compared 6-year follow-up data from patients undergoing reduced-intensity conditioning (RIC) transplantation with an HLA-matched related donor (MRD), an HLA-matched unrelated donor (MUD), or an HLA-haploidentical donor (HID) for leukemia. Four hundred and twenty-seven patients from the China RIC Cooperative Group were enrolled, including 301 in the MRD, 79 in the HID, and 47 in the MUD groups. The conditioning regimen involved fludarabine combined with anti-lymphocyte globulin and cyclophosphamide...
November 18, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27861292/long-term-tolerance-toward-haploidentical-vascularized-composite-allograft-transplantation-in-a-canine-model-using-bone-marrow-or-mobilized-stem-cells
#8
Jeff Chang, Scott S Graves, Tiffany Butts-Miwongtum, George E Sale, Rainer Storb, David Woodbridge Mathes
BACKGROUND: The development of safe and reliable protocols for the transplantation of the face and hands may be accomplished with animal modeling of transplantation of vascularized composite allografts (VCA). Previously, we demonstrated that tolerance to a VCA could be achieved after canine recipients were simultaneously given marrow from a dog leukocyte antigen-identical donor. In the present study, we extend those findings across a dog leukocyte antigen mismatched barrier. METHODS: Eight recipient dogs received total body irradiation (4...
December 2016: Transplantation
https://www.readbyqxmd.com/read/27856368/haploidentical-transplantation-with-post-transplant-cyclophosphamide-for-high-risk-acute-lymphoblastic-leukemia
#9
Samer A Srour, Denái R Milton, Asad Bashey, Amado Karduss-Urueta, Monzr Al Malki, Rizwan Romee, Scott Solomon, Stacey Brown, Michael Slade, Rosendo Perez, Gabriela Rondon, Stephan J Forman, Richard E Champlin, Partow Kebriaei, Stefan O Ciurea
Haploidentical transplantation performed with post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been associated with favorable outcomes for patients with acute myeloid leukemia and lymphomas. However, it remains unclear if such approach is effective for patients with acute lymphoblastic leukemia (ALL). We analyzed outcomes of 109 consecutively treated ALL patients 18 years of age and older at 5 institutions. The median age was 32 years and the median follow-up for survivors was 13 months...
November 14, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27853082/early-improvement-in-marrow-fibrosis-following-haploidentical-stem-cell-transplantation-for-a-patient-with-myelodysplastic-syndrome-with-bone-marrow-fibrosis
#10
Shuichiro Takahashi, Riko Tsumanuma, Keiko Aizawa, Mitsumasa Osakabe, Kunihiko Maeda, Ejiro Omoto
The prognosis for myelodysplastic syndrome with bone marrow fibrosis (MDS-F) is worse than the prognosis of MDS without fibrosis. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy; however, the indications and the procedures involved in HSCT remain unclear. We herein describe a 69-year-old Japanese man with MDS-F who received haploidentical HSCT and post-transplantation cyclophosphamide. Although the first HSCT resulted in secondary graft failure, the second HSCT using PTCy led to successful engraftment after early improvement in fibrosis...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27846611/comparable-composite-endpoints-after-hla-matched-and-hla-haploidentical-transplantation-with-posttransplantation-cyclophosphamide
#11
Shannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, Javier Bolaños-Meade, Hua-Ling Tsai, Margaret M Showel, Jennifer A Kanakry, Heather J Symons, Ivana Gojo, B Douglas Smith, Maria P Bettinotti, William H Matsui, Amy E Dezern, Carol Ann Huff, Ivan Borrello, Keith W Pratz, Douglas E Gladstone, Lode J Swinnen, Robert A Brodsky, Mark J Levis, Richard F Ambinder, Ephraim J Fuchs, Gary L Rosner, Richard J Jones, Leo Luznik
Composite endpoints that not only encompass mortality and relapse, but other critical posttransplant events such as graft-versus-host disease, are being increasingly utilized to quantify survival without significant morbidity after allogeneic blood or marrow transplantation. High-dose, posttransplantation cyclophosphamide reduces severe graft-versus-host disease after allogeneic marrow transplantation, making its composite endpoints of particular interest. We retrospectively analyzed 684 adults with hematologic malignancies who received T-cell-replete bone marrows and posttransplantation cyclophosphamide after myeloablative HLA-matched related (n= 192) or unrelated (n=120), or nonmyeloablative HLA-haploidentical (n = 372) donor transplantation; median follow up was 4 (range 0...
October 20, 2016: Haematologica
https://www.readbyqxmd.com/read/27842860/-haploidentical-hematopoietic-stem-cell-transplantation-guidelines-from-the-francophone-society-of-marrow-transplantation-and-cellular-therapy-sfgm-tc
#12
Stéphanie Nguyen, Yves Chalandon, Claude Lemarie, Sophie Simon, Dominique Masson, Nathalie Dhedin, Felipe Suarez, Barbara Renaud, Amandine Charbonnier, Nabil Yafour, Sylvie François, Rémy Duléry, Didier Blaise, Ibrahim Yakoub-Agha, Marie-Thérèse Rubio
Haploidentical hematopoietic stem cell transplantation (HSCT) is being increasingly used due to improvement of the transplantation procedures allowing a reduction of graft-versus-host-disease (GVHD) and of transplant-related mortality (TRM). Such improvements have been particularly observed after administration of T-replete HSCT graft associated to an in vivo T cell depletion by the administration of high-doses of cyclophosphamide (HD-Cy) after transplantation. Here, we have analyzed the results of haplo-identical T replete HSC transplants, in particular, when performed with post-transplant HD-Cy in order to provide recommendations for the clinical practice...
November 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27832981/haploidentical-bone-marrow-transplantation-with-post-transplant-cyclophosphamide-for-children-and-adolescents-with-fanconi-anemia
#13
Carmem Bonfim, Lisandro Ribeiro, Samantha Nichele, Gisele Loth, Marco Bitencourt, Adriana Koliski, Cilmara Kuwahara, Ana Luiza Fabro, Noemi F Pereira, Daniela Pilonetto, Monica Thakar, Hans-Peter Kiem, Kristin Page, Ephraim J Fuchs, Mary Eapen, Ricardo Pasquini
We describe haplo-identical bone marrow transplantation with post-transplant cyclophosphamide (PT-CY) for 30 patients with Fanconi anemia (FA). Twenty-six were transplanted upfront and the preparatory regimens included fludarabine (FLU) 150mg/m(2) + total body irradiation (TBI) 200-300cGy +/- CY 10mg/kg without (n=12) or with rabbit ATG (r-ATG) 4-5mg/kg (n=14). Four patients were rescued after primary or secondary graft failure after related or unrelated donor transplantation with above regimen with (n=2) or without r-ATG (n=2)...
November 7, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27819686/prior-history-of-hla-mismatched-stem-cell-transplantation-is-a-risk-factor-for-graft-failure-in-hla-haploidentical-transplantation
#14
J Sugita, T Miyamoto, N Kawashima, N Hatsumi, N Anzai, H Kaneko, M Nara, K Minauchi, M Harada, T Teshima
No abstract text is available yet for this article.
November 7, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27797369/association-of-epstein-barr-virus-reactivation-with-the-recovery-of-cd4-cd8-double-negative-t-lymphocytes-after-haploidentical-hematopoietic-stem-cell-transplantation
#15
Z Bian, J Liu, L-P Xu, Y-J Chang, Y Wang, X-H Zhang, X-J Huang
EBV infection is one of the life-threatening clinical complications in patients who underwent haploidentical hematopoietic stem cell transplantation (haploHSCT). Although immune recovery is recognized to be crucial for decreasing subsequent morbidity of infections, the link between T-cell recovery and EBV infection after haploHSCT remains elusive. We recently compared the influences of different doses of antithymocyte globulin conditioning on the T-cell reconstitution post haploHSCT and suggested that CD4(-)CD8(-)T cells might interact with the occurrence of EBV reactivation...
October 31, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27797365/comparable-post-relapse-outcomes-between-haploidentical-and-matched-related-donor-allogeneic-stem-cell-transplantation
#16
Y-R Ma, L-P Xu, X-H Zhang, C-H Yan, Y Wang, F-R Wang, J-Z Wang, Y Chen, W Han, Y-H Chen, H Chen, K-Y Liu, X-J Huang
We investigated the impact of donor type on post-relapse survival (PRS) in 85 patients with hematological relapse after their first allogeneic hematological stem cell transplantation (allo-HSCT) for hematological malignancy. The median follow-up was 64 months among survivors. Both 3-year overall survival and 3-year PRS were similar in haploidentical donor (HID) and matched sibling donor (MRD) transplantation (13.0%±4.7% vs 19.4%±7.1%, P=0.913 and 7.7±3.9% vs 9.7±5.3%, P= 0.667). Higher rates of post-relapse grade II-IV and III-IV acute GvHD (aGvHD) were observed in HID transplantation patients...
October 31, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27788764/haploidentical-cord-transplantation-the-best-of-both-worlds
#17
REVIEW
Koen van Besien, Richard Childs
Haploidentical (haplo)-cord transplantation combines infusion of an umbilical cord blood (UCB) unit with CD34-selected cells usually from human leukocyte antigen (HLA) mismatched donors. Initial rapid count recovery from the haplo-hematopoietic progenitors, is gradually replaced by durable engraftment from UCB progenitors. UCB grafts used for haplo-cord are smaller, but better matched than those required for single or double UCB stem cell transplant (SCT). More than 200 patients with hematological malignancies have been transplanted...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788763/haploidentical-transplants-using-ex-vivo-t-cell-depletion
#18
REVIEW
Massimo F Martelli, Franco Aversa
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27788762/selecting-the-best-haploidentical-donor
#19
REVIEW
Shannon R McCurdy, Ephraim J Fuchs
The substantial evidence of the safety of human leukocyte antigen (HLA)-haploidentical (haplo) blood or marrow transplantation (BMT) has led to its increasing utilization. When prioritizing HLA-matched grafts, patients frequently have few or no donors from whom to choose. However, a given patient may have multiple suitable haplo donors. Therefore factors other than HLA-match become critical for selecting the best donor. We recommend a donor selection algorithm based on the donor-specific antibodies, ABO match, donor age, donor sex, and cytomegalovirus (CMV) serostatus match...
October 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27786275/evaluating-frequency-and-quality-of-pathogen-specific-t-cells
#20
Nadia Anikeeva, Dolores Grosso, Neal Flomenberg, Yuri Sykulev
It is generally accepted that enumeration and characterization of antigen-specific T cells provide essential information about potency of the immune response. Here, we report a new technique to determine the frequency and potency of antigen-specific CD8 T cells. The assay measures changes of intracellular Ca(2+) in real time by fluorescent microscopy in individual CD8 T cells responding to cognate peptides. The T cells form continuous monolayer, enabling the cells to present the peptides to each other. This approach allows us to evaluate the kinetics of intracellular Ca(2+) signalling that characterizes the quality of T cell response...
October 27, 2016: Nature Communications
keyword
keyword
13298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"